Citation of paper, Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

Authors Citing This Paper

AuthorCiting PapersAuthor's PapersAuthor's CitationsAuthor's IF
Denis L Jardim1222252.7
Cássia Rita Pereira da Veiga16100.9
Julien Sarkis127330.8
Rebecca Shay1231.5
Tobias Engel1923,5234.9
Elaine T Lam1441,8187.9

Journals Citing This Paper